Genentech Invests In Singapore ... | Chemical & Engineering News
Volume 85 Issue 14 | p. 26 | Concentrates
Issue Date: April 2, 2007

Genentech Invests In Singapore ...

Department: Business

Genentech will build a $140 million biologics plant in Singapore. Expected to open in 2010, the plant will be the first in Singapore to make microbial fermentation-based pharmaceuticals. It will employ 100 people and initially produce Genentech's Lucentis treatment for wet macular degeneration. The biologics plant will join three already under construction in Singapore. GlaxoSmithKline is building a vaccines facility, and contract manufacturer Lonza is constructing two facilities, one of which Genentech has an option to acquire.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment